Bioavailability Studies
In the realm of autoimmune disease drug research and development, bioavailability studies play a critical role in assessing the extent and rate at which a drug's active ingredient is absorbed and becomes available at the site of action. As a research service provider, Protheragen delves into all aspects of bioavailability research and demonstrate the excellent services we provide in this field.
Introduction to Bioavailability Studies
Bioavailability (BA) refers to the proportion of an administered drug that reaches the systemic circulation in an unchanged form and becomes available for the desired pharmacological effect. It is a fundamental concept in pharmacology that determines the effectiveness of a drug in producing the desired therapeutic response. Bioavailability studies aim to quantify and understand the factors influencing the absorption, distribution, metabolism, and excretion (ADME) of drug compounds.
These studies typically involve comparing the pharmacokinetic (PK) measurements of the drug target in the systemic system following different dosing routes, such as oral administration, intravenous injection, or other routes specific to the drug. By assessing BA early in the drug discovery process, researchers can identify potential issues and make informed decisions to optimize drug formulation and delivery strategies, ultimately reducing attrition rates.
Fig.1 Graph of concentration of drug in the body vs time. (Patel Di., et al., 2020)
Bioavailability Study in Drug Development
In the intricate landscape of drug development, bioavailability studies serve as a vital tool to evaluate the PK profile and therapeutic effectiveness of drug compounds.
Early Drug Discovery
During the early stages of drug discovery, bioavailability studies are conducted to assess the BA of potential drug candidates. By understanding the absorption characteristics of different compounds, researchers can prioritize the most promising candidates for further development, potentially saving time and resources.
Formulation Development
Once potential drug candidates are identified, formulation development becomes crucial to optimize drug delivery and enhance bioavailability. Bioavailability studies help in evaluating different formulations, including immediate-release, extended-release, and novel delivery systems.
Comparative Bioavailability Assessment
Comparative bioavailability studies are conducted to compare the BA of different drug formulations or routes of administration. This assessment is vital for ensuring therapeutic equivalence, especially in cases of generic drug products, biosimilars, or changes in manufacturing.
Our Services
As a renowned leader in the field of autoimmune diseases and inflammation, our company has been at the forefront of bioavailability and bioequivalence testing. We take immense pride in offering exceptional services, driven by our team of highly skilled pharmacokineticists and state-of-the-art facilities.
| Animal Species |
|---|
| Mouse, Rat, Pig, Dog, Monkey, Others |
| Dosing Routes |
| Oral administration (PO), Intraperitoneal (IP), Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC), Others |
| Dosage Forms |
| Controlled release (CR), Immediate release (IR), Extended-release (ER), Solid oral, Orally dispersible tablets (ODT), Others |
| Test Content |
| Absolute bioavailability testing, Comparative bioavailability testing, Bioequivalence testing Analysis of PK parameters: Tmax, Cmax, AUC∞, AUC0-t, t1/2, Ke, C0, Vd, Others |
Why Choose Us?
Bioavailability studies play a pivotal role in autoimmune diseases and inflammation drug development by providing vital insights into the absorption and therapeutic efficacy of drug compounds. Our company, as a trusted leader in this field, offers comprehensive bioavailability studies services, supported by our team of experts, cutting-edge facilities, and extensive experience. If you are interested in our services, please don't hesitate to contact us.
Reference
- Patel Divya, Dhwani Desai, and Falgun A. Mehta. "A Review on the Importance of In-vitro Bioavailability and Bioequivalence Studies." J Pharmacol Toxicol 2.2 (2020): 49-70.